A Phase 1/2, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of IPH6501 in Patients with Relapsed and/or Refractory CD20-expressing Non-Hodgkin Lymphoma
This research study is looking at a new treatment called IPH6501 for a specific type of blood cancer: non-Hodgkin lymphoma. This includes people whose cancer has come back (relapsed) or hasn't responded to previous treatments (refractory). The main goals of this early-stage study are to find a safe and effective dose of IPH6501, and to understand any side effects people might experience. We will also check if the medicine helps to shrink or control the cancer. By testing this new drug, researchers hope to find better ways to treat non-Hodgkin lymphoma in the future.
At a glance
What is this study about?
This study is about a new medicine called IPH6501, which is being tested for people living with non-Hodgkin lymphoma with a specific marker called CD20. Non-Hodgkin lymphoma is a type of cancer that starts in white blood cells called lymphocytes. For some people, unfortunately, the cancer can come back after treatment (this is called 'relapsed') or it might not respond to treatments they've already had (this is called 'refractory'). This study is specifically for these situations.
The main aim of this early study (called Phase 1/2) is to see how safe the new medicine, IPH6501, is and what dose works best without causing too many problems. We'll be carefully watching for any side effects and how well people cope with the treatment. We also want to get an early idea of whether IPH6501 can help to stop the cancer from growing or even shrink it.
By taking part, you would be helping doctors and scientists learn more about new ways to treat non-Hodgkin lymphoma. This kind of research is really important for developing future medicines that could help many others.
Key takeaways
- This study is testing a new drug (IPH6501) for non-Hodgkin lymphoma.
- It's for people whose cancer has returned or didn't respond to previous treatments.
- The main goals are to check safety, find the best dose, and see if it helps fight the cancer.
- Participation involves regular hospital visits for treatment and checks.
- You must be 18 or older to take part.
- You can stop participating at any time if you wish.
Who may be eligible?
To be able to join this study, there are a few important things that need to be true for you. First, you must be at least 18 years old – there's no upper age limit, so people of all adult ages can be considered. The study is also open to both men and women.
The most important medical requirement is that you have a specific type of non-Hodgkin lymphoma where the cancer cells have a particular marker called CD20. Also, your cancer must have either come back after previous treatment, or it hasn't responded well to treatments you've tried before.
There will be other health checks and tests to make sure that taking part in the study would be safe for you. The study team will explain all of these carefully to make sure it's the right choice.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Have you been diagnosed with non-Hodgkin lymphoma with a CD20 marker?
- Has your non-Hodgkin lymphoma come back after treatment, or not responded to past treatments?
- Are you able to attend regular hospital visits for check-ups and treatment?
What does participation involve?
If you decide to take part in this study, you would receive the new medicine, IPH6501. The study team will explain exactly how it will be given. You would have regular visits to the hospital or clinic so the doctors can check on your health and see how you are responding to the treatment. These visits will likely include blood tests, physical examinations, and possibly scans to see how the cancer is doing.
The study will first focus on finding the right dose and checking for safety. This means some people might start on a lower dose and it could be increased gradually. The total time you would be involved in the study would depend on how your body responds to the treatment and the study plan, but it will involve ongoing check-ups for a period of time. The study team will give you a clear schedule of what to expect.
Potential risks and benefits
Locations (1)
- —UnverifiedFrance
Common questions
What is IPH6501?
IPH6501 is a new medicine being tested to treat a type of blood cancer called non-Hodgkin lymphoma.
What type of cancer is this study for?
It's for people with non-Hodgkin lymphoma that has a specific marker (CD20) and has either come back or not responded to previous treatments.
What does 'Phase 1/2' mean?
It means this is an early study to check if the new medicine is safe and to find the best dose, and also to see if it starts to show benefits against the cancer.
Will I know if the medicine is working?
The study doctors will do regular tests and scans to check how your cancer is responding and will discuss the results with you.
Can I leave the study if I change my mind?
Yes, you can always choose to stop participating in the study at any time without it affecting your medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.